Immune checkpoint inhibitors and cancer-associated thrombosis: an overview
Immune checkpoint inhibitors (ICIs) are a type of immunotherapy that revolutionized cancer treatment and, in recent...
Therapy
Summary ESMO Clinical Practice Guideline for the management of venous thromboembolism in cancer patients
Venous thromboembolism (VTE) is the second cause of death in people with cancer, after cancer itself. Cancer and VTE...
The Impact of DDI on the Cancer Patient
Cancer patients are often prescribed more than one drug and the need to elucidate potential harmful interactions...
What do we know about bleeding risk in patients with cancer?
Venous thromboembolism (VTE) is a well-recognized complication in patients with cancer, with an increase in risk by a...
DEBATE: Should VTE treatment continue beyond six months? The evidence behind the decision to continue anticoagulation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...
DEBATE: Should VTE treatment continue beyond 6 months? Evidence supporting anticoagulation discontinuation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...
Evolving data on cardiovascular complications in cancer
During the 11th ICTHIC, Hugo Ten Cate talked about the evolving data on cardiovascular complications in cancer. Here,...
Thrombosis management in hematological cancers vs solid tumors: what are the differences?
During the ICTHIC webinar “CAT management: challenges in different cancer populations,” Prof Darko Antic...
VTE risk in patients with ovarian cancer undergoing neoadjuvant chemotherapy.
Ovarian cancer is the ninth most common type of cancer and the seventh most common cause of cancer death in women . In...
Coagulation proteases, DOACs and their clinical impact on checkpoint inhibitor therapy
The hemostatic system in cancer The hemostatic system forms an integral part of the innate immune system and...